Intracranial stenting, injecting clot-busting drugs directly to brain

February 25, 2010

Techniques that keep brain arteries open (intracranial stenting) or inject clot-busting drugs directly to the brain (intra-arterial tPA) may be more effective than other urgent ischemic stroke treatments, researchers said at the American Stroke Association's International Stroke Conference 2010.

In a study of 1,056 severe patients treated with one or more therapies within eight hours of symptom onset, blood flow was restored in 76 percent of stented patients and 72 percent of those receiving the clot-busting drug (tPA) directly to the brain (intra-arterial tPA). Overall, blood flow was restored in only 69 percent of patients treated with other drug techniques or interventions.

is caused by blockages in a vessel in or leading to the .

Researchers studied several treatment techniques:

  • intra-arterial tPA
  • intracranial stenting
  • intravenous delivery of tPA via the arm
  • Merci Retriever™ - a corkscrew-like device that is threaded into the blocked blood vessel to grab and pull out clots
  • Prenumbra™ aspiration catheter - uses suction to remove blood clots
  • glycoprotein IIb/IIIa antagonists
  • angioplasty (without stenting)
But only results for intra-arterial tPA and intracranial stenting reached statistical significance.

"Essentially, there is no standard currently as to which interventions are performed for acute stroke in this country," said Rishi Gupta, M.D., senior author of the study and an assistant professor at Vanderbilt University Medical Center's Department of Neurology in Nashville, Tenn. "We decided to study treatment at 12 of the busiest stroke centers in the country to determine which of the therapies currently in use may be yielding the best results in terms of opening the blood vessel without creating hemorrhage."

Researchers said 534 patients received more than one therapy and 75 percent of the time (or in 400 patients), it was successful.
The next phase of the study will examine whether the initial success of these two treatments continues through three months of follow-up, he said.

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.